| 1. |
Benson AB, D’Angelica MI, Abbott DE, et al. Hepatobiliary cancers, version 2. 2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2021, 19(5): 541-565.
|
| 2. |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版). 中华消化外科杂志, 2022, 21(2): 143-168.
|
| 3. |
Chong JU, Choi GH, Han DH, et al. Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol, 2018, 25(11): 3308-3315.
|
| 4. |
Zhu XD, Huang C, Shen YH, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations. Liver Cancer, 2021, 10(4): 320-329.
|
| 5. |
梁斌, 张航宇, 冯健, 等. 累及下腔静脉巨大肝癌转化治疗成功并根治性切除一例. 中华肝胆外科杂志, 2020, 26(4): 307-308, 309.
|
| 6. |
Kim HC, Lee JH, Chung JW, et al. Transarterial chemoembolization with additional cisplatin infusion for hepatocellular carcinoma invading the hepatic vein. J Vasc Interv Radiol, 2013, 24(2): 274-283.
|
| 7. |
Kim YJ, Jung J, Joo JH, et al. Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: necessity to subclassify Barcelona Clinic Liver Cancer stage C. Radiother Oncol, 2019, 141: 95-100.
|
| 8. |
Kokudo T, Hasegawa K, Matsuyama Y, et al. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey. Hepatology, 2017, 66(2): 510-517.
|
| 9. |
van Lienden KP, van den Esschert JW, de Graaf W, et al. Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol, 2013, 36(1): 25-34.
|
| 10. |
谢坤, 耿小平. 门静脉栓塞在肝切除术前的临床运用. 肝胆外科杂志, 2013, 21(6): 475-477.
|
| 11. |
Park GC, Lee SG, Yoon YI, et al. Sequential transcatheter arterial chemoembolization and portal vein embolization before right hemihepatectomy in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int, 2020, 19(3): 244-251.
|
| 12. |
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, 2018, 391(10126): 1163-1173.
|
| 13. |
张雯雯, 胡丙洋, 韩骏, 等. PD-1抑制剂与多靶点酪氨酸激酶抑制剂联合方案用于进展期肝癌转化治疗研究的初步报告. 中华肝胆外科杂志, 2020, 26(12): 947-948.
|
| 14. |
胡丙洋, 张雯雯, 周黔川, 等. 巴塞罗那C期肝癌靶向联合免疫降期转化后实施左半肝切除术一例. 中华肝胆外科杂志, 2020, 26(1): 65-67.
|
